ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Acetic Acid → (+/-)-2-[4-(4-Amino-quinazolin-7-ylmethyl)-3-methoxycarbonyl-5-oxo-piperazin-1-ylmethyl]-5-chloro-indole-1-carboxylic acid tert-butyl ester

HRID 1433012
ノート
印刷プレビュー

反応式

HRID 1433012 の反応式
[C:1]([O:5][C:6]([N:8]1[C:16]2[C:11](=[CH:12][C:13]([Cl:17])=[CH:14][CH:15]=2)[CH:10]=[C:9]1[CH2:18][N:19]1[CH2:24][C:23](=[O:25])[N:22]([CH2:26][C:27]2[CH:32]=C[C:30](C#N)=[C:29](N)[CH:28]=2)[CH:21]([C:36]([O:38][CH3:39])=[O:37])[CH2:20]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[N:40]1[CH:45]=[N:44][CH:43]=[N:42][CH:41]=1.CC(O)=O>CCO>[C:1]([O:5][C:6]([N:8]1[C:16]2[C:11](=[CH:12][C:13]([Cl:17])=[CH:14][CH:15]=2)[CH:10]=[C:9]1[CH2:18][N:19]1[CH2:24][C:23](=[O:25])[N:22]([CH2:26][C:27]2[CH:32]=[C:41]3[C:30]([C:45]([NH2:40])=[N:44][CH:43]=[N:42]3)=[CH:29][CH:28]=2)[CH:21]([C:36]([O:38][CH3:39])=[O:37])[CH2:20]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]
参加物実験手順後処理出典と根拠反応ノート

参加物

5

反応物 3

HCID 176Acetic Acid2 回HCID 92621,3,5-Triazine2 回HCID 54288444(+/-)-2-[4-(3-Amino-4-cyano-benzyl)-3-methoxycarbonyl-5-oxo-piperazin-1-ylmethyl]-5-chloro-indole-1-carboxylic acid tert-butyl ester

生成物 1

HCID 53785442(+/-)-2-[4-(4-Amino-quinazolin-7-ylmethyl)-3-methoxycarbonyl-5-oxo-piperazin-1-ylmethyl]-5-chloro-indole-1-carboxylic acid tert-butyl ester収率 24.9%

試薬・触媒・溶媒 1

HCID 702Ethanol溶媒

実験手順

A solution containing (±)-2-[4-(3-amino-4-cyano-benzyl)-3-methoxycarbonyl-5-oxo-piperazin-1-ylmethyl]-5-chloro-indole-1-carboxylic acid tert-butyl ester (100 mg, 0.18 mmol), 1,3,5-triazine (146 mg, 1.81 mmol), and glacial HOAc (99 mg, 1.81 mmol) in absolute EtOH (10 mL) is maintained at reflux for 16 hours. A second portion of 1,3,5-triazine (146 mg, 1.81 mmol) and glacial HOAc (99 mg, 1.81 mmol) is added and the reaction mixture is maintained at reflux for an additional 16 hours. The reaction mixture is concentrated in vacuo and the crude product is diluted with water/CH3CN and purified by reverse-phase HPLC [Buffer A: water w/0.1% TFA; Buffer B: CH3CN w/0.1% TFA; Gradient: 0% B to 60% B over 30 min] to provide 26 mg (20%) of the title compound as a white solid which is used directly in the next reaction without further characterization.

後処理

  1. temperatureis maintained
  2. temperatureat reflux for 16 hours
  3. temperaturethe reaction mixture is maintained
  4. temperatureat reflux for an additional 16 hours
  5. concentrationThe reaction mixture is concentrated in vacuo
  6. additionthe crude product is diluted with water/CH3CN
  7. custompurified by reverse-phase HPLC [Buffer A: water

出典と根拠

ORDレコード
ord-cee5dbd33fd143108fdaeb94cacefb81
出典データセット
uspto-grants-2009_11
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07612075B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート